Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. (A) Sézary syndrome patient before treatment

Published byKatrina Cook Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2. (A) Sézary syndrome patient before treatment"— Presentation transcript:

1 Figure 2. (A) Sézary syndrome patient before treatment
Figure 2. (A) Sézary syndrome patient before treatment. (B) Sézary syndrome patient after three courses of therapy. From: Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome) Ann Oncol. 2014;25(9): doi: /annonc/mdu231 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

2 Figure 1. (A) Mycosis fungoides patient before treatment
Figure 1. (A) Mycosis fungoides patient before treatment. (B) Mycosis fungoides patient after 10 weeks of treatment. From: Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome) Ann Oncol. 2014;25(9): doi: /annonc/mdu231 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

Download ppt "Figure 2. (A) Sézary syndrome patient before treatment"

Similar presentations

From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Fig. 1 Graphical representation

Fig. 1 Graphical representation
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Error bars represent the mean (s.e.).

Error bars represent the mean (s.e.).
Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p

Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser
Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.
Fig. 1. Geographic locations of Shenzhen and Dongguan

Fig. 1. Geographic locations of Shenzhen and Dongguan
Figure 1 (A) Chest computed tomography scans of the patient

Figure 1 (A) Chest computed tomography scans of the patient

Similar presentations

Ads by Google